특성,NME**,생물학적,백신
1단계에서 2단계로,50.6%,52.5%,52%
2단계에서 3단계로,25.6%,32.4%,32.2%
NDA/BLA*에 대한 3단계,50.6%,56.7%,58.1%
NDA/BLA 승인*,86.1%,94.6%,100%
